U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula I2
Molecular Weight 253.80894
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Iodine

SMILES

II

InChI

InChIKey=PNDPGZBMCMUPRI-UHFFFAOYSA-N
InChI=1S/I2/c1-2

HIDE SMILES / InChI
Molecular Formula I2
Molecular Weight 253.80894
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Tetraglycine hydroperiodide is an iodine-containing chemical, used for water purification. Tetraglycine hydroperiodide is marketed in tablets; each tablet effectively disinfects 1 liter of clear water or 0.5 liter of tainted water by releasing approximately 8 mg free iodine. It requires approximately 30 minutes to inactivate target microorganisms and make water bacteriologically suitable for drinking. To remove iodine taste, a vitamin C pill is added to the kit.

Approval Year

1921
1468
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
Surgicide

Approved Use

Surgicide is a broad spectrum topical antiseptic for use on skin and mucous membranes. Use solution without dilution as needed
PubMed

PubMed

TitleDatePubMed
Developmental iodine deficiency delays the maturation of newborn granule neurons associated with downregulation of p35 in postnatal rat hippocampus.
2014-08
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry.
2013-01
Opposing regulation of cytochrome P450 expression by CAR and PXR in hypothyroid mice.
2012-09-01
The effects of ammonium perchlorate on thyroid homeostasis and thyroid-specific gene expression in rat.
2012-08
A blinded, randomized, palatability study comparing variations of 2 popular field water disinfection tablets.
2011-12
I-131 dose response for incident thyroid cancers in Ukraine related to the Chornobyl accident.
2011-07
Use of gadolinium for carotid artery angiography and stenting in patients with renal insufficiency.
2009-12
[The effects of iodine/selenium on the function of antigen presentation of peritoneal macrophages in rats].
2008-07
Gadolinium and kidney disease: are your patients at risk?
2008-05-14
[Suggestions for prevention of adverse reactions after intravasal administration of iodinated contrast media].
2008
Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC).
2007-11
Comparison of the usefulness of gadodiamide and iodine mixture versus iodinated contrast alone for prevention of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography.
2007-10-01
Sodium iodide symporter is expressed at the preneoplastic stages of liver carcinogenesis and in human cholangiocarcinoma.
2007-04
[Effects of iodine excess and selenium supplement on the levels of thyroid hormone and its receptor expression in filial cerebrum of mice].
2007-03
Enhanced expression of adenovirus-mediated sodium iodide symporter gene in MCF-7 breast cancer cells with retinoic acid treatment.
2007-03
Goiter and other iodine deficiency disorders: A systematic review of epidemiological studies to deconstruct the complex web.
2007-01
Comparative cytotoxicity of high-osmolar and low-osmolar contrast media on HKCs in vitro.
2006-12-19
Antiseptics, iodine, povidone iodine and traumatic wound cleansing.
2006-11
The treatment of Graves' disease in children.
2006-09
Synergistic regulation of endothelial tight junctions by antioxidant (Se) and polyunsaturated lipid (GLA) via Claudin-5 modulation.
2006-08-01
Effect of selenium supplementation on activity and mRNA expression of type 1 deiodinase in mice with excessive iodine intake.
2006-08
Molecular iodine induces caspase-independent apoptosis in human breast carcinoma cells involving the mitochondria-mediated pathway.
2006-07-14
Salt dual-fortified with iodine and micronized ground ferric pyrophosphate affects iron status but not hemoglobin in children in Cote d'Ivoire.
2006-07
The loss of the chloride channel, ClC-5, delays apical iodide efflux and induces a euthyroid goiter in the mouse thyroid gland.
2006-03
Involvement of tumor necrosis factor-alpha in sulfur mustard-induced skin lesion; effect of topical iodine.
2005-11
Reverse transcriptase inhibitors down-regulate cell proliferation in vitro and in vivo and restore thyrotropin signaling and iodine uptake in human thyroid anaplastic carcinoma.
2005-10
[Effect of high-iodine intake on MBP mRNA expression in cerebrum of filial mice and selenium intervention].
2005-07
Inhibition of N-methyl-N-nitrosourea-induced mammary carcinogenesis by molecular iodine (I2) but not by iodide (I-) treatment Evidence that I2 prevents cancer promotion.
2005-05-31
Thyrotropin-secreting pituitary adenoma responsive to bromocriptine therapy.
2004-07-15
Studies on experimental iodine allergy: 3. Low molecular weight elicitogenic antigens of iodine allergy.
2004-05
Thiocyanate induces cell necrosis and fibrosis in selenium- and iodine-deficient rat thyroids: a potential experimental model for myxedematous endemic cretinism in central Africa.
2004-02
Synergistic interaction between excess caffeine and deficient iodine on the promotion of thyroid carcinogenesis in rats pretreated with N-bis(2-hydroxypropyl)nitrosamine.
2003-04
Functional expression of sodium iodide symporter (NIS) in human breast cancer tissue.
2003-01
Effects of selenium and iodine on the expression of c-fos and c-jun mRNA and their proteins in cultured rat hippocampus neurons.
2002-06
Effects of selenium and iodine on c-fos and c-jun mRNA and their protein expressions in cultured rat hippocampus cells.
2002
Effects of iodine on inducible nitric oxide synthase and cyclooxygenase-2 expression in sulfur mustard-induced skin.
2001-02
Anti-goitrous effect of lecithin-bound iodine in propylthiouracil treated rats.
2000-06
Adverse reactions to nonionic iodine in contrast-enhanced computed tomography: usefulness of monitoring vital signs.
1998-07
Propylthiouracil-induced rapidly progressive glomerulonephritis associated with antineutrophil cytoplasmic autoantibodies.
1997-07
Case report: reversible mitral regurgitation and congestive heart failure complicating thyrotoxicosis.
1996-03
Thyroid adaptation to chronic tetraglycine hydroperiodide water purification tablet use.
1995-01
Subfulminant hepatitis requiring liver transplantation after benzarone administration.
1994-06
[Necrotizing hepatitis with a fatal outcome after carbimazole therapy].
1993-10-22
The susceptibility of the fetus and child to chemical pollutants. Special susceptibility of the host to chemical agents: endocrinologic considerations.
1974-05
Patents

Patents

20030153532
9
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:00:43 GMT 2025
Edited
by admin
on Mon Mar 31 18:00:43 GMT 2025
Record UNII
9679TC07X4
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IODIUM
HPUS  
Preferred Name English
Iodine
EP   HSDB   II   MART.   MI   USP   VANDF   WHO-DD   WHO-IP  
Systematic Name English
IODINE [USP MONOGRAPH]
Common Name English
IODINE [HSDB]
Common Name English
NSC-42355
Code English
IODIUM [HPUS]
Common Name English
IODINE STRONG [VANDF]
Common Name English
IODINE [EP IMPURITY]
Common Name English
IODINE [WHO-IP]
Common Name English
JODOSAN
Common Name English
IODINE [MI]
Common Name English
Iodine [WHO-DD]
Common Name English
IODINE [EP MONOGRAPH]
Common Name English
IODINE [II]
Common Name English
IODINE [VANDF]
Common Name English
IODINE [JAN]
Common Name English
TEGODYNE
Common Name English
IODINE MILD [VANDF]
Common Name English
IODINE [MART.]
Common Name English
IODINE STRONG
VANDF  
Common Name English
IODUM [WHO-IP LATIN]
Common Name English
Classification Tree Code System Code
LOINC 25448-2
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
LOINC 50868-9
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
LOINC 34321-0
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
WHO-VATC QD08AG03
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
LOINC 34320-2
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
LOINC 76657-6
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
LOINC 55928-6
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
LOINC 53872-8
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
LOINC 25936-6
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
LOINC 25449-0
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
NCI_THESAURUS C896
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
WHO-ATC D08AG03
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
WHO-VATC QD08AG53
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
EPA PESTICIDE CODE 46905
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
LOINC 2494-3
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
LOINC 44323-4
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
LOINC 26842-5
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
LOINC 2492-7
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
DSLD 184 (Number of products:5290)
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
DEA NO. 6699
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 27
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
LOINC 2495-0
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
Code System Code Type Description
CHEBI
17606
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
PRIMARY
MESH
D007455
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
PRIMARY
NCI_THESAURUS
C594
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
PRIMARY
HSDB
34
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
PRIMARY
CAS
7553-56-2
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
PRIMARY
WIKIPEDIA
Tincture of iodine
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
PRIMARY
ECHA (EC/EINECS)
231-442-4
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
PRIMARY
MERCK INDEX
m6327
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
PRIMARY Merck Index
DAILYMED
9679TC07X4
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
PRIMARY
WIKIPEDIA
Iodine (medical use)
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
PRIMARY
PUBCHEM
807
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
PRIMARY
FDA UNII
9679TC07X4
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
PRIMARY
EVMPD
SUB14239MIG
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
PRIMARY
DRUG BANK
DB05382
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
IODINE
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
PRIMARY Description: Heavy, greyish black plates or granules, having a metallic lustre. Solubility: Very slightly soluble in water; soluble in ethanol (~750 g/l) TS; freely soluble in carbon tetrachloride R, carbon disulfide R, and ether R. Category: External antiseptic. Storage: Iodine should be kept in a tightly closed container, preferably made of glass and provided with a glass stopper. Additional information: Iodine volatilizes slowly at room temperature giving violet, irritant vapours. Definition: Iodine contains not less than 99.5% and not more than 100.5% of I.
NSC
42355
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
PRIMARY
RXCUI
5933
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
PRIMARY RxNorm
DRUG CENTRAL
4446
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
PRIMARY
LACTMED
Iodine
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
PRIMARY
SMS_ID
100000092589
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
PRIMARY
EPA CompTox
DTXSID7034672
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
PRIMARY
CHEBI
24859
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201225
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
PRIMARY
WIKIPEDIA
Iodine
Created by admin on Mon Mar 31 18:00:43 GMT 2025 , Edited by admin on Mon Mar 31 18:00:43 GMT 2025
PRIMARY
Related Record Type Details
Structure of IODINE I-123
LABELED -> NON-LABELED
Related Record Type Details
Structure of Iodine
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966